The New England journal of medicine
-
Randomized Controlled Trial Multicenter Study
Mepolizumab treatment in patients with severe eosinophilic asthma.
Some patients with severe asthma have frequent exacerbations associated with persistent eosinophilic inflammation despite continuous treatment with high-dose inhaled glucocorticoids with or without oral glucocorticoids. ⋯ Mepolizumab administered either intravenously or subcutaneously significantly reduced asthma exacerbations and was associated with improvements in markers of asthma control. (Funded by GlaxoSmithKline; MENSA ClinicalTrials.gov number, NCT01691521.).
-
Editorial Comment
FFR-guided PCI--FAME may not be so fleeting after all.
-
Randomized Controlled Trial Multicenter Study Comparative Study
Fractional flow reserve-guided PCI for stable coronary artery disease.
We hypothesized that in patients with stable coronary artery disease and stenosis, percutaneous coronary intervention (PCI) performed on the basis of the fractional flow reserve (FFR) would be superior to medical therapy. ⋯ In patients with stable coronary artery disease, FFR-guided PCI, as compared with medical therapy alone, improved the outcome. Patients without ischemia had a favorable outcome with medical therapy alone. (Funded by St. Jude Medical; FAME 2 ClinicalTrials.gov number, NCT01132495.).